Heteroaryl substituted aminopyridine compounds

US10202390B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• John V. Duncia · Newtown, US
• Daniel S. Gardner · Furlong, US
• John Hynes · Washington Crossing, US
• John E. Macor · Guilford, US
• Satheesh Kesavan Nair · Kanchinakote, IN
• Venkatram Reddy Paidi · Bengaluru, IN
• Joseph B. Santella · Springfield, US
• Kandhasamy Sarkunam · Hosur, IN
• Ramesh Kumar Sistla · Bengaluru, IN
• Subba Rao Polimera · Bengaluru, IN
• Hong Wu · Meekrap-oord, CN

Key dates

• Filing date: Jun 23, 2016
• Grant date: Feb 12, 2019
• Expiry date: Jun 23, 2036

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are compounds of Formula (I) or salts thereof, wherein: HET is a heteroaryl selected from imidazo[1,2-b]pyridazinyl and pyrazolo[1,5-a]pyrimidinyl, wherein said heteroaryl is attached to the pyridinyl group in the compound of Formula (I) by a carbon ring atom in the heteroaryl and wherein said heteroaryl is substituted with zero to 2 Rb; A is pyrazolyl, imidazolyl, or triazolyl, each substituted with zero or 1 Ra; and R3, Ra, and Rb are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.